Dr Michael Tarzi

Dr Michael Tarzi

Consultant Immunologist

MA (Cantab) MD MRCP FRCPath

I specialise in the diagnosis and management of allergic conditions and related disorders. I have particular expertise in the following areas: the medical management of allergic rhinitis and 'desensitisation' treatments for allergens such as pollen, dust mite and animal danders, insect venom allergy, urticaria and angioedema, anaphylaxis and food allergy.

My immunology expertise also includes immunodeficiency disorders, and although this field is no longer my main focus I can provide a general opinion in most settings.

I have been involved in allergy services and research since 2001, when I joined the Allergy Department at the National Heart and Lung Institute as a junior doctor and clinical research fellow. Specialty training in Clinical Immunology followed from 2003, based at The Royal London Hospital and The Royal Free Hospital. I moved to Brighton in 2008, taking up a new role as Senior Lecturer and Consultant Immunologist. Professor Frew and I forged a productive partnership to grow and develop the fairly new Allergy Clinic at The Royal Sussex County Hospital. In 2012 the service was recognised as the regional provider for Sussex, and I took over leadership in 2019.

My caseload extends to several thousand appointments per year. Around 600 patients have completed desensitisation programmes under my supervision.

I hold a number of leadership positions at University Hospitals Sussex NHS Foundation Trust, primarily based on The Royal Sussex County site: Clinical Lead for Allergy Services; Clinical Lead for Diagnostic Immunology; Clinical Lead for Blood Sciences. I hold a Senior Lecturer position at Brighton & Sussex Medical School, and lead the year 2 immunology education theme.

Read more...

Treatment information

Some of the principal treatments carried out by Dr Michael Tarzi at Spire include:

Allergy

Immunology

Other treatments

  • Investigation and management of allergic and related disorders, with a particular interest in desensitisation treatment for severe rhinitis.

Get in touch

136220
True
consultant

Marketing Information

Spire would like to provide you with marketing information about products and services offered by Spire and by selected third-party partners. If you do not consent for us to process your personal data for marketing activities, we will still be able to contact you about your enquiry.

We may contact you by email, SMS or phone about your enquiry. If we try to contact you by phone (mobile and/or landline) and you are not available, we may leave you a voicemail message. We may also use your details to contact you about patient surveys we use for improving our service or monitoring outcomes, which are not a form of marketing.

We will use your personal information to process your enquiry. For further information, please see our privacy policy.

Submit my enquiry

Additional information

Allergy
Immunology

Special clinical interests: Investigation and management of allergic and related disorders, with a particular interest in desensitisation treatment for severe rhinitis.

Articles

Kudsiova L, Lansley A, Scutt G, Allen M, Bowler L, Williams S, Lippett S, Stafford S, Tarzi M, Cross M, Okorie M. Stability testing of the Pfizer-BioNTech BNT162b2 COVID-19 vaccine: a translational study in UK vaccination centres. BMJ Open Sci. 2021 Sep 12;5(1):e100203.

Gray NJ, Redshaw EL, Isaacs D, Tarzi MD, Smith HE, Frew AJ. Allergy in the elderly: A case note review of referrals to an adult allergy clinic. Clinical & Experimental Allergy. 2018 Sep;48(9):1238-41.

Longhurst H, Cicardi M, Craig T, Bork K, Grattan C, Baker J, Li HH, Reshef A, Bonner J, Bernstein JA, Anderson J. Prevention of hereditary angioedema attacks with a subcutaneous C1 inhibitor. New England Journal of Medicine. 2017 Mar 23;376(12):1131-40.

Longhurst HJ, Tarzi MD, Ashworth F, Bethune C, Cale C, Dempster J, Gompels M, Jolles S, Seneviratne S, Symons C, Price A. C1 inhibitor deficiency: 2014 United Kingdom consensus document. Clinical & Experimental Immunology. 2015 Jun;180(3):475-83.

Beltran L, Koenig M, Egner W, Howard M, Butt A, Austin MR, Patel D, Sanderson RR, Goubet S, Saleh F, Lavender J, Stainer E, Tarzi MD. High-titre circulating tissue transglutaminase-2 antibodies predict small bowel villous atrophy, but decision cut-off limits must be locally validated. Clin Exp Immunol 2014, 176(2):190-198.

Jolles S, Williams P, Carne E, Mian H, Huissoon A, Wong G, Hackett S, Lortan J, Platts V, Longhurst H, Grigoriadou S, Dempster J, Deacock S, Khan S, Darroch J, Simon C, Thomas M, Pavaladurai V, Alachkar H, Herwadkar A, Abinun M, Arkwright P, Tarzi M, Helbert M, Bangs C, Pastacaldi C, Phillips C, Bennett H, El-Shanawany T. A UK national audit of hereditary and acquired angioedema. Clin Exp Immunol 2014; 175: 59-67.

Beltran L, Koenig M, Egner W, Howard M, Butt A, Austin MR, Patel D, Sanderson RR, Goubet S, Saleh F, Lavender J, Stainer E, Tarzi MD. High-titre circulating TTG2 antibodies predict small bowel villous atrophy, but decision cut-off limits must be locally validated. Clin Exp Immunol 2013 (epublished ahead of print)

Smith KA, Gray NJ, Saleh F, Cheek E, Frew AJ, Kern F, Tarzi MD. Characterisation of CD154+ T cells following ex vivo allergen stimulation illustrates distinct T cell responses to seasonal and perennial allergens in allergic and non-allergic individuals. BMC Immunol 2013;14: 49.

Smith KA, Gray NJ, Cheek E, Saleh F, Lavender J, Frew AJ, Kern F, Tarzi MD. Characterisation of CD154+ T cells following ex vivo birch allergen stimulation defines a close relationship between T cell subsets in healthy volunteers. BMC Immunol 2013;14: 14.

Rashid RS, Smith KA, Nambiar KZ, Frew AJ, Tarzi MD. Pollen-food syndrome is related to Bet v 1/PR-10 protein sensitisation, but not all patients have spring rhinitis. Allergy 2011;66: 1391-1392.

Rizzi M, Neumann C, Fielding AK, Marks R, Goldacker S, Thaventhiran J, Tarzi MD, Schlesier M, Salzer U, Eibel H, Warnatz K, Finke J, Grimbacher B, Peter HH. Outcome of allogeneic stem cell transplantation in adults with common variable immunodeficiency. J Allergy Clin Immunol 2011;128: 1371-1374.

Tarzi MD, Grigoriadou S, Carr SB, Kuitert LM, Longhurst HJ. Clinical immunology review series: An approach to the management of pulmonary disease in primary antibody deficiency. Clin Exp Immunol 2009; 155:147-55.

Yong PF, Tarzi M, Chua I, Grimbacher B, Chee R. Common variable immunodeficiency: an update on etiology and management. Immunol Allergy Clin North Am 2008; 28:367-86, ix-x.

Tarzi MD, Hickey A, Forster T, Mohammadi M, Longhurst HJ. An evaluation of tests used for the diagnosis and monitoring of C1 inhibitor deficiency: normal serum C4 does not exclude hereditary angioedema. Clin Exp Immunol 2007; 149:513-6.

Tarzi M, Klunker S, Texier C, Verhoef A, Stapel SO, Akdis CA, et al. Induction of interleukin-10 and suppressor of cytokine signalling-3 gene expression following peptide immunotherapy. Clin Exp Allergy 2006; 36:465-74.

Alexander C, Tarzi M, Larche M, Kay AB. The effect of Fel d 1-derived T-cell peptides on upper and lower airway outcome measurements in cat-allergic subjects. Allergy 2005; 60:1269-74.

Khan S, Tarzi MD, Dore PC, Sewell WA, Longhurst HJ. Secondary systemic lupus erythematosus: an analysis of 4 cases of uncontrolled hereditary angioedema. Clin Immunol 2007; 123:14-7.

Tarzi MD, Jenner M, Hattotuwa K, Faruqi AZ, Diaz GA, Longhurst HJ. Sporadic case of warts, hypogammaglobulinemia, immunodeficiency, and myelokathexis syndrome. J Allergy Clin Immunol 2005; 116:1101-5.

Tarzi MD, Lightman S, Longhurst HJ. An exacerbation of Behcet's syndrome presenting with bilateral papillitis. Rheumatology (Oxford) 2005; 44:953-4.

Tarzi M, Larche M. Peptide immunotherapy for allergic disease. Expert Opin Biol Ther 2003; 3:617-26.

Senior Lecturer in Immunology, Brighton and Sussex Medical School.

Consultant Immunologist, University Hospitals Sussex NHS Foundation Trust.

In my spare time, I try to keep fit and spend time with friends and family.